scholarly journals Improved Virological Outcome in Non-B Patients: A Possible Role for Baseline Coreceptor Tropism

2012 ◽  
Vol 55 (1) ◽  
pp. 165-167 ◽  
Author(s):  
L. Monno ◽  
L. Scudeller ◽  
A. Saracino ◽  
C. R. Santoro ◽  
A. Lagioia ◽  
...  
Keyword(s):  
Coreceptor Tropism ◽  
Virological Outcome

Poor clinical and virological outcome of nucleos(t)ide therapy in HBV/HDV co-infected patients

2020 ◽  
Author(s):  
L Scheller ◽  
G Hilgard ◽  
OA Anastasiou ◽  
U Dittmer ◽  
A Kahraman ◽  
...  
Keyword(s):  
Virological Outcome

scholarly journals Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen

2018 ◽  
Vol 73 (4) ◽  
pp. 1039-1044 ◽  
Author(s):  
Charlotte Charpentier ◽  
Isabelle Malet ◽  
Elisabeth Andre-Garnier ◽  
Alexandre Storto ◽  
Laurence Bocket ◽  
...  
Keyword(s):  
Integrase Inhibitor ◽  
Phenotypic Analysis ◽  
Virological Outcome ◽  
Hiv 1

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients

AIDS ◽  
2013 ◽  
Vol 27 (1) ◽  
pp. 69-80 ◽  
Author(s):  
Lucile Larrouy ◽  
Alexandre Vivot ◽  
Charlotte Charpentier ◽  
Antoine Bénard ◽  
Benoit Visseaux ◽  
...  
Keyword(s):  
Genetic Determinants ◽  
Virological Outcome

scholarly journals Newborn virological outcome after intrauterine ZIKV exposure

2018 ◽  
Vol 73 ◽  
pp. 375
Author(s):  
A.C. Bernardes Terzian ◽  
C.F. Estofolete ◽  
N. Nery-Junior ◽  
N. Zini ◽  
G. Celestino Dutra Da Silva ◽  
...  
Keyword(s):  
Virological Outcome

scholarly journals Virological measures and factors associated with outcomes, and missing outcome data in HIV clinical trials: a methodological study

BMJ Open ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. e039462
Author(s):  
Mark Youssef ◽  
Babalwa Zani ◽  
Oluwatobi Olaiya ◽  
Michael Soliman ◽  
Lawrence Mbuagbaw
Keyword(s):  
Missing Data ◽  
Outcome Data ◽  
Controlled Trials ◽  
People Living With Hiv ◽  
Cochrane Central Register ◽  
Pharmacological Interventions ◽  
Factors Associated ◽  
Multiple Measures ◽  
Virological Outcome ◽  
Virological Outcomes

BackgroundTo evaluate the definition of HIV virological outcomes in the literature and factors associated with outcomes and missing outcome data.MethodsWe conducted a methodological review of HIV RCTs using a search (2009–2019) of PubMed, Embase and the Cochrane Central Register of Controlled Trials.Only full-text, peer-reviewed, randomised controlled trials (RCTs) that measured virological outcomes in people living with HIV, and published in English were included.We extracted study details and outcomes. We used logistic regression to identify factors associated with a viral threshold ≤50 copies/mL and linear regression to identify factors associated with missing outcome data.ResultsOur search yielded 5847 articles; 180 were included. A virological outcome was the primary outcome in 73.5% of studies. 89 studies (49.4%) used virological success. The remaining used change in viral load (VL) (33 studies, 18.3%); virological failure (59 studies, 32.8%); or virological rebound (9 studies, 5.0%). 96 studies (53.3%) set the threshold at ≤50 copies/mL; and 33.1% used multiple measures.Compared with government and privately funded studies, RCTs with industry funding (adjusted OR 6.39; 95% CI 2.15 to 19.00; p<0.01) were significantly associated with higher odds of using a VL threshold of ≤50 copies/mL. Publication year, intervention type, income level and number of patients were not associated with a threshold of ≤50 copies/mL. Trials with pharmacological interventions had less missing data (β=−11.04; 95% CI −20.02 to −1.87; p=0.02).DiscussionCountry source of funding was associated with VL threshold choice and studies with pharmacological interventions had less missing data, which may in part explain heterogeneous virological outcomes across studies. Multiple measures of VL were not associated with missing data. The development of formal guidelines on virological outcome reporting in RCTs is needed.

scholarly journals Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy

AIDS ◽  
2018 ◽  
Vol 32 (3) ◽  
pp. 357-361 ◽  
Author(s):  
Gwamaka E. Mwasakifwa ◽  
Cecilia Moore ◽  
Dianne Carey ◽  
Janaki Amin ◽  
Paul Penteado ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Second Line ◽  
Virological Outcome ◽  
Second Line Antiretroviral Therapy

Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs

AIDS ◽  
2003 ◽  
Vol 17 (6) ◽  
pp. 821-830 ◽  
Author(s):  
David A Katzenstein ◽  
Ronald J Bosch ◽  
Nicholas Hellmann ◽  
Nan Wang ◽  
Lee Bacheler ◽  
...  
Keyword(s):  
Antiretroviral Drugs ◽  
Virological Outcome ◽  
Phenotypic Susceptibility

Longer Term Clinical and Virological Outcome of Sub-Saharan African Participants on Antiretroviral Treatment in the Swiss HIV Cohort Study

2012 ◽  
Vol 59 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Cornelia Staehelin ◽  
Olivia Keiser ◽  
Alexandra Calmy ◽  
Rainer Weber ◽  
Luigia Elzi ◽  
...  
Keyword(s):  
Cohort Study ◽  
Antiretroviral Treatment ◽  
Virological Outcome ◽  
Sub Saharan

scholarly journals Coreceptor Tropism Can Be Influenced by Amino Acid Substitutions in the gp41 Transmembrane Subunit of Human Immunodeficiency Virus Type 1 Envelope Protein

2008 ◽  
Vol 82 (11) ◽  
pp. 5584-5593 ◽  
Author(s):  
Wei Huang ◽  
Jonathan Toma ◽  
Signe Fransen ◽  
Eric Stawiski ◽  
Jacqueline D. Reeves ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Amino Acid ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Envelope Protein ◽  
Variable Region ◽  
Single Amino Acid ◽  
Coreceptor Tropism ◽  
Immunodeficiency Virus

ABSTRACT Many studies have demonstrated that the third variable region (V3) of the human immunodeficiency virus type 1 (HIV-1) envelope protein (Env) is a major determinant of coreceptor tropism. Other regions in the surface gp120 subunit of Env can modulate coreceptor tropism in a manner that is not fully understood. In this study, we evaluated the effect of env determinants outside of V3 on coreceptor usage through the analysis of (i) patient-derived env clones that differ in coreceptor tropism, (ii) chimeric env sequences, and (iii) site-directed mutants. The introduction of distinct V3 sequences from CXCR4-using clones into an R5-tropic env backbone conferred the inefficient use of CXCR4 in some but not all cases. Conversely, in many cases, X4- and dual-tropic env backbones containing the V3 sequences of R5-tropic clones retained the ability to use CXCR4, suggesting that sequences outside of the V3 regions of these CXCR4-using clones were responsible for CXCR4 use. The determinants of CXCR4 use in a set of dual-tropic env sequences with V3 sequences identical to those of R5-tropic clones mapped to the gp41 transmembrane (TM) subunit. In one case, a single-amino-acid substitution in the fusion peptide of TM was able to confer CXCR4 use; however, TM substitutions associated with CXCR4 use varied among different env sequences. These results demonstrate that sequences in TM can modulate coreceptor specificity and that env sequences other than that of V3 may facilitate efficient CXCR4-mediated entry. We hypothesize that the latter plays an important role in the transition from CCR5 to CXCR4 coreceptor use.

Sign in / Sign up

Export Citation Format

Share Document